Sale by Parker Albert P of 3173 shares of Zynerba Pharmaceuticals

Read at macroaxis.com

Published over a year ago View all stories for Zynerba Pharmaceuticals | Zynerba Pharmaceuticals Hype Analysis

Zynerba insider trading alert for sale of common stock by Parker Albert P, Chief Legal Officer, on 17th of February 2023. This event was filed by Zynerba Pharmaceuticals I with SEC on 2023-02-17. Statement of changes in beneficial ownership - SEC Form 4

We analyze Zynerba Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zynerba Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zynerba Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Zynerba Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Zynerba Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Zynerba Pharmaceuticals by comparing valuation metrics with similar companies.

Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

If you are still planning to invest in Zynerba Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Zynerba Pharmaceuticals' history and understand the potential risks before investing.